Valion Bio (VIBO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Jul, 2026Executive summary
Special Meeting scheduled for August 14, 2026, will be held virtually to maximize accessibility for all shareholders.
Only holders of common stock as of July 7, 2026, are entitled to vote; preferred stockholders have no voting rights for this meeting.
Two main proposals: reverse stock split authorization and potential adjournment to solicit more proxies.
Board unanimously recommends voting FOR both proposals.
Voting matters and shareholder proposals
Proposal 1: Authorize the board to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50 within twelve months of approval, at the board's discretion.
Proposal 2: Allow the board to adjourn the meeting if more time is needed to solicit proxies for Proposal 1.
Both proposals require a majority of shares present or represented by proxy to pass; abstentions count as votes against.
Board recommends voting FOR both proposals.
Advance notice procedures for shareholder proposals and director nominations for the 2027 annual meeting are outlined.
Board of directors and corporate governance
Board has authority to determine the reverse split ratio and timing, or to abandon the split if deemed unnecessary.
Board has adopted a written policy for reviewing and approving related party transactions.
No director or executive officer has a material interest in the proposals beyond their equity holdings.
Latest events from Valion Bio
- Shareholders approved board authority for a reverse stock split and potential meeting adjournment.VIBO
EGM 2026 - Net loss widened on higher R&D and CDMO costs, with urgent need for new funding and Nasdaq compliance risks.VIBO
Q2 2026 - Biopharma pivots to Entolimod, raising up to $13.7M via flexible share/warrant offering.VIBO
Registration filing - Shareholders will vote on a reverse stock split to maintain Nasdaq compliance and potential adjournment authority.VIBO
Proxy filing - All proposals passed as the company advances its clinical-stage biopharma strategy.VIBO
AGM 2026 - Q1 2026 saw higher expenses, net loss, and liquidity risks amid strategic transformation.VIBO
Q1 2026 - Shareholders will vote on director election, equity plan, auditor, and major share issuance approvals.VIBO
Proxy filing - Board recommends approval of director, equity plan, auditor, and major share issuance proposals.VIBO
Proxy filing - Late-stage immune therapies advance toward approval, with Entolimod targeting ARS and neutropenia.VIBO
Emerging Growth Conference 91